City briefs: Abingdon Health and OptiBiotix
York-headquartered medical diagnostics tests producer, Abingdon Health, says its subsidiary company, CS (Lifesciences) Ltd, has won a contract with a major global diagnostics company.
This is for work relating to quality management systems and regulatory approvals. The contract will begin in March 2025 and continue for 12 months, providing revenue of more than £500,000 spread across that period.
Abingdon Health acquired CS (Lifesciences) Ltd, a consultancy specialising in meeting compliance requirements in international IVD and medical device markets, in August 2024.
Edwin Lindsay, managing director of CS (Lifesciences) Ltd, said: “I am pleased that we can announce this contract win with a major entity in the medical diagnostics sector.
“It illustrates that our focused skilled personnel are able to offer specialised expertise in quality and regulatory approval which is competitive and appealing to even the major players in the in vitro diagnostics sector.”
Chris Yates, CEO of Abingdon, added: “This contract win illustrates one aspect of Abingdon’s service offering in the medical diagnostic sector and to the wider med-tech industry.
“Our full CDMO (Contract Development and Manufacturing Organisation) service, offering services to an international customer base, has been enhanced by our recent acquisition of CS (Lifesciences) Ltd, and I congratulate Edwin and the team on this contract win with a major diagnostics company.”
:::
OptiBiotix Health, a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, has confirmed David Blain has been appointed to its Board as finance director and company secretary effective from 7 January 2025.
Blain is a member of the Institute of Chartered Accountants in England and Wales and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc).
Blain is currently financial director (non-board position) at Iksuda Therapeutics Ltd.
His appointment to this part-time role will see him work with the OptiBiotix team to support the focus on driving each business unit and the group to profitability.
Stephen O’Hara, CEO of York-headquartered OptiBiotix, said: “We are pleased to confirm the appointment of David as finance director and company secretary.
“The appointment reflects the Board’s focus on managing costs and building revenues to create profitable business units and an international business with well-known global brands.”
